MiMedx Group (NASDAQ:MDXG) Posts Quarterly Earnings Results

MiMedx Group (NASDAQ:MDXG) announced its quarterly earnings data on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05), FiscalAI reports. The company had revenue of $64.36 million for the quarter, compared to analysts’ expectations of $63.46 million. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%.

Here are the key takeaways from MiMedx Group’s conference call:

• Sanara MedTech acquisition: MiMedx agreed to acquire Sanara for $35 per share, creating a combined regenerative medicine company expected to generate more than $400 million in 2027 revenue, double-digit growth, over 20% adjusted EBITDA margins, and at least $20 million in annual cost synergies.
• Surgical momentum remained strong: Second-quarter surgical revenue increased 15% year over year, with broad-based growth across the portfolio, while the Sanara deal is expected to expand MiMedx’s surgical addressable market by approximately $4 billion.
• Wound care showed early stabilization: Wound revenue rose 11% sequentially and volume increased 22%, including 44% sequential growth in wound care centers, but revenue remained down 61% year over year because of substantially reduced Medicare reimbursement and ongoing administrative challenges.
• Second-quarter profitability deteriorated: Net sales fell 35% year over year to $64 million, adjusted EBITDA was negative $8 million, and gross margin declined to 69%; results included an additional $5 million bad-debt charge tied mainly to private-office accounts.
• Financing and outlook: MiMedx reiterated 2026 standalone revenue guidance of $260 million to $290 million and expects adjusted EBITDA to approach breakeven, while financing the Sanara acquisition with a $300 million term loan carrying interest at SOFR plus 6.25%.

MiMedx Group Stock Performance

Shares of MDXG stock traded down $0.13 during midday trading on Wednesday, hitting $4.23. 1,421,925 shares of the company were exchanged, compared to its average volume of 1,279,335. The firm has a market capitalization of $629.61 million, a P/E ratio of 21.14 and a beta of 1.45. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39. The firm’s 50 day moving average price is $3.89 and its two-hundred day moving average price is $4.27. MiMedx Group has a 52 week low of $3.03 and a 52 week high of $7.99.

Institutional Investors Weigh In On MiMedx Group

A number of institutional investors have recently made changes to their positions in the company. SkyView Investment Advisors LLC grew its position in shares of MiMedx Group by 3.6% in the second quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock valued at $523,000 after purchasing an additional 3,032 shares during the last quarter. Rafferty Asset Management LLC increased its stake in shares of MiMedx Group by 4.6% during the fourth quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock worth $469,000 after purchasing an additional 3,064 shares during the period. Aviva PLC lifted its holdings in MiMedx Group by 4.7% during the 4th quarter. Aviva PLC now owns 71,234 shares of the company’s stock worth $482,000 after purchasing an additional 3,211 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after purchasing an additional 4,049 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in MiMedx Group by 42.6% in the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after purchasing an additional 4,296 shares during the period. Institutional investors own 79.15% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MDXG shares. Citizens Jmp decreased their target price on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 18th. Craig Hallum cut their price target on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, Wall Street Zen downgraded shares of MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, MiMedx Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.